ArticleCancer research2021
Hormonal Regulation of Semaphorin 7a in ER
Open access · bronzeAbstract read
In one paragraph
Article in Cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 42 citations in OpenAlex.
- Phase II study of apatinib plus exemestane in estrogen receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer.Cancer biology & therapy · 2023Trial
- Distinguishing Ki67 stratification expression in ER-positive/HER2-negative breast cancers: comparison of advanced MRI diffusion models.BMC medical imaging · 2026Article
- SOX9 and SEMA7A regulate cell plasticity in the postpartum mammary gland with implications for breast cancer.bioRxiv : the preprint server for biology · 2026Article
- Targeting Semaphorin 7a signaling in preclinical models of endocrine therapy-resistant breast cancer.Molecular cancer therapeutics · 2026Article
- The long noncoding RNA AC093895.1 promotes ovarian cancer formation and metastasis through a positive feedback network dependent on the transcription factor SOX4.Cell death & disease · 2026Article
- Semaphorin-7A promotes macrophage-mediated mammary epithelial and ductal carcinoma in situ invasion.Breast cancer research : BCR · 2025Article
- Cold atmospheric plasma restores fulvestrant sensitivity by inhibiting CCND3 in the drug-resistant breast cancer cells.Scientific reports · 2025Article
- Aging-induced semaphorin 7a promotes TGF-β1-mediated cell plasticity and breast tumor metastases.Cell reports · 2025Article
- Targeting Resistance Pathways in Breast Cancer Through Precision Oncology: Nanotechnology and Immune Modulation Approaches.Biomedicines · 2025Review
- Bimodal Genomic Approach Predicting Semaphorin 7A (SEMA7A) as Prognostic Biomarker in Adrenocortical Carcinoma.Cancers · 2025Article
- Semaphorin7A and PD-L1 cooperatively drive immunosuppression during mammary involution and breast cancer.Cell reports · 2025Article
- Bimodal genomic approach predicting Semaphorin 7A (SEMA7A) as prognostic biomarker in adrenocortical carcinoma.bioRxiv : the preprint server for biology · 2025Article
- Tumor-derived SEMA7A regulates fatty acid oxidation in the tumor-associated macrophages to promote the progression of non-small cell lung cancer.Frontiers in immunology · 2025Article
- SEMA7A-mediated juxtacrine stimulation of IGFBP-3 upregulates IL-17RB at pancreatic cancer invasive front.Cancer gene therapy · 2024Article
- Article
- Employing Piezoelectric MgAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- A comprehensive review on lncRNA LOXL1-AS1: molecular mechanistic pathways of lncRNA LOXL1-AS1 in tumorigenicity of cancer cells.Frontiers in oncology · 2024Review
- Analyzing aberrant DNA methylation in colorectal cancer uncovered intangible heterogeneity of gene effects in the survival time of patients.Scientific reports · 2023Article
- Current Advances and Future Strategies for BCL-2 Inhibitors: Potent Weapons against Cancers.Cancers · 2023Review
- Semaphorins and Their Roles in Breast Cancer: Implications for Therapy Resistance.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Lyndsey S CrumpDivision of Medical Oncology, Department of Medicine, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
Garhett L WyattDepartment of Veterinary Integrative Biosciences, Texas A&M University, College Station, Texas.ORCID https://orcid.org/0000-0001-7402-6404
Taylor R RutherfordDivision of Medical Oncology, Department of Medicine, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
Jennifer K RicherDepartment of Pathology, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado.ORCID https://orcid.org/0000-0002-9960-0991
Weston W PorterDepartment of Veterinary Integrative Biosciences, Texas A&M University, College Station, Texas.
Traci R LyonsDivision of Medical Oncology, Department of Medicine, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado. traci.lyons@cuanschutz.edu.
University of Colorado Cancer Center · USTexas A&M University · USUniversity of Colorado Anschutz Medical Campus · US
Funding
University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0MDeciphering COX-2/SEMA7A dependent mechanisms of breast tumor progression.R01CA211696 · NCI · UNIVERSITY OF COLORADO DENVER · PI LYONS, TRACI · 2017 to 2021
$2.0MAndrogen Receptor and Intersecting Pathways Critical to Breast Cancer SubtypesR01CA187733 · NCI · UNIVERSITY OF COLORADO DENVER · PI RICHER-MOUCHANTAT, JENNIFER · 2015 to 2019
$1.9MTranscriptional regulation of differentiation gene expressionR01HD083952 · NICHD · TEXAS A&M AGRILIFE RESEARCH · PI PORTER, WESTON W, RIJNKELS, MONIQUE · 2016 to 2020
$1.5MColorado Clinical and Translational Sciences InstituteTL1TR001081 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2013 to 2017
$1.3M(PQA1)Toward understanding mechanisms of COX-2 driven metastasis of breast cancerR21CA185226 · NCI · UNIVERSITY OF COLORADO DENVER · PI LYONS, TRACI · 2014 to 2015
$371kDiet-dependent regulation of DCIS progressionR21CA197896 · NCI · TEXAS A&M AGRILIFE RESEARCH · PI PORTER, WESTON W · 2016 to 2017
$355kHormonal Regulation and Tumor Promotional Phenotypes of Semaphorin 7a in Breast CancerF31CA236140 · NCI · UNIVERSITY OF COLORADO DENVER · PI CRUMP, LYNDSEY S · 2019 to 2021
$91kNCATS NIH HHS TL1 TR001081NCI NIH HHS F31 CA236140NCI NIH HHS P30 CA046934NCI NIH HHS R01 CA187733NCI NIH HHS R01 CA211696NCI NIH HHS R21 CA185226NCI NIH HHS R21 CA197896NICHD NIH HHS R01 HD083952
Abstract
Approximately 70% of all breast cancers are estrogen receptor-positive (ER
Indexed as
Drug Resistance, NeoplasmAnimalsAntigens, CDAntineoplastic Agents, HormonalApoptosisBiomarkers, TumorBreast NeoplasmsCell MovementCell ProliferationEstrogensFemaleGPI-Linked ProteinsHumansMiceMice, Inbred NODMice, SCIDAntigens, CDAntineoplastic Agents, HormonalBiomarkers, TumorEstrogensGPI-Linked ProteinsReceptors, EstrogenSEMA7A protein, humanSemaphorins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.